Echo Therapeutics pursues CE mark for wireless glucose monitoring system; Volcano lowers 2014 guidance;

@FierceMedDev: Appeals court reaffirms injunction on Boston Scientific's Guidezilla catheter. More | Follow @FierceMedDev

@MarkHFierce: Detailed medical imaging of the skin is drawing investor interest in the U.K. Release | Follow @MarkHFierce

@MichaelGFierce: ICYMI: Global nanomed market, driven by brain delivery, is expected to reach $177B by 2019. Item from FierceDrugDelivery | Follow @MichaelGFierce

@EmilyWFierce: O.C. medical device firm sees great potential in Indian market, expands sales. More | Follow @EmilyWFierce

> Volcano ($VOLC) now expects revenue to grow 4% to 6% in 2014, down from earlier predictions of 9% to 11% growth. The maker of surgical tools to help diagnose and treat coronary and peripheral vascular disease said it expects a softer global market and fewer procedures in Japan. Item

> Echo Therapeutics submitted a CE mark application for its Symphony CGM System, a non-invasive, wireless continuous glucose monitoring system. Item

> The U.K.'s Michelson Diagnostics nailed down $3.25 million in new financing, in part to support sales expansion in Germany for its VivoSight medical imaging system, which non-invasively looks at all layers of the skin in precise detail. Item

> Providence Medical Technology has nailed down 5 U.S. patents in recent months affecting joint implants and how they are placed inside the body. Item

> Excelsior Medical gained a 510(k) clearance for its disinfection cap, which works to disinfect a valve surface for up to a week. Item

> Enable Injections of Franklin, OH, is trying to bring a painless drug injector to market before some much larger rivals do the same. Story

Biotech News

@FierceBiotech: Merck's fast and furious MK-3475 #immunotherapy team guns for a quick approval. Story | Follow @FierceBiotech

@JohnCFierce: Interesting to see Sanofi and Roche going deeper into RNAi as Merck bails out, takes a big writeoff for Sirna. Makes sense, though. In or out. | Follow @JohnCFierce

@DamianFierce: With $125M Alexion deal, Moderna has pulled in more than $500M over the past year and change. More | Follow @DamianFierce

@EmilyMFierce: European industry-academic partnership seeks miRNA therapies for neurodegenerative diseases. Article | Follow @EmilyMFierce

> GSK dumps a failed muscular dystrophy drug back in Prosensa's lap. Story

> Cell Therapeutics buoyed as Novartis deals are terminated. More

> Sanofi grabs a $700M stake in Alnylam as it ups the ante on RNAi. News

Pharma News

@FiercePharma: AC Immune begins first trial of a tau-targeting Alzheimer's vaccine. Story from FierceVaccines | Follow @FiercePharma

@TracyStaton: And still FiercePharma's best-read special report: Top 10 Drug Patent Losses of 2014. Report | Follow @TracyStaton

@EricPFierce: There are 3,000 compounding pharmacies making sterile drugs. Just 11 have volunteered for FDA oversight. Story from FiercePharmaManufacturing | Follow @EricPFierce

@CarlyHFierce: Adcock Ingram forges ahead with its African expansion while CFR deal stalls. Friday's story | Follow @CarlyHFierce

> FDA's latest action further imperils Ranbaxy's U.S. sales. Story

> Look for an M&A scramble in 2014, with pharma chasing deals at ever-higher prices. Report

> Chinese corruption probe expands as officials detain former Sinopharm exec. More

CRO News

> Quintiles partners up to boost its commercialization business. More

> Theorem aligns with BioTelemetry to dial up its cardiac market share. Report

> CROS NT buys into biometrics with its latest acquisition. News

> Pfizer taps risk-sharing researcher Avillion for cancer PhIII. Story

> JSS eyes Canadian dominance with buyout of rival CRO. Article

> GoBalto goes global with expansion into U.K. and Singapore. Item

Biotech IT News

> New York Genome Center taps U. of Buffalo for computing horsepower. Report

> Pfizer trialing video game designed to diagnose Alzheimer's. Item

> Merge wipes $15M from backlog after discovering ex-employee faked contracts. News

> Merck invests in an FDA-cleared mobile diabetes management business. Article

> Analyst: CROs like Covance and Icon will take the lead on IT and genomics. Story

> Early Google investor picks Maverix from the genome data analysis crowd. More

Suggested Articles

J&J’s Ethicon unit received an FDA clearance for its Vistaseal applicators that spray a biologic sealant from Grifols to help stem surgical bleeding.

Bio-Techne’s urine test has received a breakthrough device designation from the FDA for ruling out unnecessary tissue biopsies.

Qiagen launched a one-stop shop compiling publicly available genomic data, scientific literature and phenotypic information on potential superbugs.